Precigen (PGEN) Earnings Date & Reports

Key Takeaways

• Total revenue reached $74.1 million for the third quarter of 2026, up from $2.9 million in the year-ago period.
• PAPZIMEOS net product revenue grew 37% quarter-over-quarter to $72.9 million, driving a return to profitability.
• Net income was $35.8 million, or $0.08 per diluted share, versus a $325.3 million net loss a year earlier.
• The company achieved positive operating cash flow of $11.9 million a full quarter ahead of its year-end guidance.
• Reported EPS of $0.08 came in slightly below the $0.09 Zacks consensus estimate, while revenue narrowly missed the $74.15 million consensus.
• For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover fresh market opportunities with Trending AI Robots, which surface AI-driven trade ideas across stocks and ETFs.

Earnings Context and Why It Matters

Precigen (PGEN) is a commercial-stage biopharmaceutical company that has undergone a rapid financial transformation since the U.S. Food and Drug Administration (FDA) approved its lead therapy, PAPZIMEOS, in August 2025. Once a pre-revenue developer of precision medicines, the company is now scaling a commercial launch in adult recurrent respiratory papillomatosis (RRP), a rare disease. The third quarter of 2026 marks a key checkpoint in that rollout: investors are watching whether PAPZIMEOS demand is durable, whether margins hold near historically high levels, and whether the company can sustain the profitability and positive cash flow it has begun to generate. These results offer a direct read on the commercial strategy that now defines Precigen's investment story.

Reported Results

Precigen reported total revenue of $74.1 million for the three months ended September 30, 2026, an increase of roughly $71.2 million from the year-ago quarter. Net product revenue from PAPZIMEOS was $72.9 million, up 37% from the second quarter, while collaboration and licensing revenue declined by $1.8 million. Gross margin came in at approximately 91%, with cost of products and services of $6.5 million. Research and development (R&D) expenses fell 46.4% year over year to $6.6 million, and selling, general, and administrative (SG&A) expenses declined 6.8% to $22.4 million.

On the bottom line, the company swung to net income of $35.8 million, or $0.10 per basic share and $0.08 per diluted share, compared with a net loss of $325.3 million, or $1.06 per share, in the prior-year period. Management highlighted that the company generated $11.9 million in cash from operating activities, reaching positive cash flow ahead of its year-end guidance. Cash and investments totaled $51 million at quarter-end. Reported earnings per share (EPS) of $0.08 fell slightly short of the $0.09 consensus estimate, while revenue missed the consensus of $74.15 million by about 1.7%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves in biotech names like Precigen, the AI Screener offers a streamlined way to surface actionable ideas.

Market Reaction and Investor Sentiment

Heading into the release, sentiment around Precigen was broadly positive, driven by the rapid uptake of PAPZIMEOS and the company's move toward profitability. Precigen shares had gained roughly 25.6% year-to-date through the report, outpacing the broader market. The market's reaction to the third-quarter results will hinge on how investors weigh a modest shortfall against consensus estimates against the more important milestone of positive operating cash flow delivered ahead of schedule. The sequential 37% revenue growth signals that commercial demand continued to build, which may reassure investors focused on the durability of the launch rather than a single-quarter comparison against analyst forecasts.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several factors that could shape Precigen's trajectory following this earnings report. First is the sustainability of PAPZIMEOS revenue growth. The therapy launched just over a year ago, and management expects continued momentum as adoption expands. Tracking new patient starts, physician adoption beyond academic centers, and payer access will be important signals of whether demand can keep accelerating.

Second is margin stability. Management has guided that gross margins on U.S. PAPZIMEOS sales should remain in the high-80s to low-90s range going forward. Any meaningful deviation from that band would be worth monitoring, as it would affect profitability and cash generation.

Third, the company's pipeline offers longer-term catalysts. Precigen is advancing a pediatric PAPZIMEOS program and a pipeline candidate, PRGN-2009, targeting HPV (human papillomavirus)-related cancers, with late-2026 data readouts expected. These milestones could expand the company's addressable market beyond its current RRP franchise.

Finally, investors should keep an eye on the balance sheet and cash position. With positive operating cash flow now achieved and $96.5 million in trade accounts receivable expected to be collected over the months following quarter-end, the company's liquidity runway and its ability to fund further commercialization without additional dilution remain key considerations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations